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In Brief
This study of the structural effects of
three mutations in cardiac myosin-
binding protein C (cMyBP-C) that are
linked to hypertrophic cardiomyopathy,
the most common forms of inherited
heart disease, contributes to our
understanding of the role of cMyBP-C in
healthy and diseased heart function.
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The structural effects of three missense mutations
clinically linked to hypertrophic cardiomyopathy
(HCM) and located in the central domains of cardiac
myosin-binding protein C (cMyBP-C) have been
determined using small-angle scattering, infrared
spectroscopy, and nuclear magnetic resonance
spectroscopy. Bioinformatics and modeling were
used to initially predict the expected structural im-
pacts and assess the broader implications for func-
tion based on sequence conservation patterns. The
experimental results generally affirm the predictions
that two of the mutations (D745G, P873H) disrupt
domain folding, while the third (R820Q) is likely to
be entirely solvent exposed and thus more likely to
have its impact through its interactions within the
sarcomere. Each of the mutations is associated
with distinct disease phenotypes, with respect to
severity, stage of onset, and end phase. The results
are discussed in terms of understanding key
structural features of these domains essential for
healthy function and the role theymay play in disease
development.
INTRODUCTION
The objective of this studywas to determine the structural effects
of three disease-linked missense mutations (D745G, R820Q,
and P873H) located in the central domains of cardiac myosin-
binding protein C to gain insight into their key structural features
essential for healthy function, and potentially some insight also
into the molecular causes for disease development. The muta-
tions chosen for study are all linked to clinical cases of hypertro-
phic cardiomyopathy (HCM), a restrictive disease of the left heart
ventricle that has been estimated to affect as many as 1 in 200
individuals (Mamidi et al., 2014). While a large proportion of in-
herited HCM cases are linked to mutations in cMyBP-C (recently
reviewed in Carrier et al., 2015), the relationship between geno-
type and phenotype has been elusive, and frustrated by the fact
that the disease has a highly heterogeneous phenotypic and ge-
netic profile (Harris et al., 2011; Lee et al., 2015).Structure 24, 10Isoforms of myosin-binding protein C (MyBP-C) are found in
vertebrate striated muscle located in the cross-bridge-bearing
C zone of the A band in the sarcomere. The name of the protein
reflects the early recognition of its myosin-binding properties,
but it also has been found to interact with thin filament actin.
The highly modular architecture of cMyBP-C comprises 11 do-
mains (C0 through C10) (Carrier et al., 1997), recently reviewed
in Sadayappan and de Tombe (2014); eight having high similarity
to immunoglobulin (Ig)-like domains (C0 through C5, plus C8
and C10) with the remaining three (C6, C7, C9) highly similar to
fibronectin (Fn)-like domains. Between the C1 and C2 domains
is a sequence of approximately 100 amino acids called the
‘‘motif,’’ which in vitro studies find contains some helical struc-
ture (Tanner et al., 2014) but is otherwise largely unstructured.
The cardiac isoform of MyBP-C (cMyBP-C) has a number of
distinctive features, including the cardiac-specific N-terminal
C0 domain, a nine-residue insertion in the motif that is a key
site for phosphorylation, and two insertions in the C5 domain
that affect its fold and stability (Idowu et al., 2003). The full-length
cMyBP-C is composed of 1,274 amino acids encoded by the
MYBPC3 gene.
We have previously reported small-angle X-ray scattering
(SAXS) studies of full-length cMyBP-C and a number of multi-
domain constructs (Jeffries et al., 2011); however, a detailed
structural study of the full-length protein is challenging due to
its large size and flexibility. There are nuclear magnetic reso-
nance (NMR) and crystal structures of individual domains,
including the cardiac-specific C5 (Idowu et al., 2003), but no
high-resolution structures of multi-domain constructs. Many
studies of cMyBP-C to date have focused on the N-terminal
modules that are proposed to interact with actin and with
the lever arm domain of myosin (S2) proximal to the myosin
head (S1) to regulate contraction, and to a lesser extent on
the C-terminal region that anchors the protein to thick filament
and titin.
The central domains inclusive of C5 through C7 are interesting
for a number of reasons. Firstly, they include the cardiac isoform-
specific C5 Ig-like domain and two adjacent Fn-like domains
(C6, C7), a unique arrangement in the protein. The cardiac-spe-
cific insertions in C5 are the 30-residue insertion in the middle
of the domain referred to as the CD loop and an additional ten-
residue insertion between the C4 and C5 domains that forms
an integral part of the C5 fold. NMR studies show that the CD
loop is highly unstructured and dynamic, resulting in the lower
stability of C5 compared with other Ig domains (Idowu et al.,5–115, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 105
2003). Secondly, a significant proportion of cMyBP-C HCM-
linked sequence variants occur in these domains and show
different patterns in frequency and type. In a review, Harris
et al. (2011) identified C6 as having the largest number of clini-
cally linked variants among all of the cMyBP-C domains,
followed closely by C5. Just over 40%of these aremissensemu-
tations for both C5 and C6. In contrast, C7 has about half the
number of HCM-linked variants and a much smaller proportion
(23%) are missense variants. While HCM-linked variants
continue to be identified and archived (Landrum et al., 2014), it
is likely that these patterns are representative. Thirdly, the muta-
tions focused on in this study have been reported to show
different disease phenotypes with regard to onset, severity,
and association with other heart conditions (Ingles et al., 2005;
Konno et al., 2003; Nanni et al., 2003; Probst et al., 2011).
We also note that the residue at position 820 in C6 in the native
protein (GenBank: NG_007667.1) was mistakenly identified in
the highly cited Carrier paper (Carrier et al., 1997) as glutamine
and not arginine, and the R820Q mutation is one of the HCM-
linked mutations that is the focus of this study. The 1997 refer-
ence is widely used for defining the cMyBP-C domain sequence
and organization, and it is useful to consider the potential impact
of this misidentification on studies that have used that sequence,
which includes our earlier SAXS studies of the full-length
cMyBP-C and a series of N-terminal constructs (Jeffries et al.,
2011). We now refer to the native sequence as containing
R820, but continue to refer to Carrier et al. (1997) for the
numbering of domains and their approximate boundaries.
In brief, our studies show that mutations in cMyBP-C linked to
HCM have distinct structural consequences that bioinformatics
and modeling largely predict. Specifically, two mutations linked
to early onset and more severe HCM interfere with domain
folding (D745G and P873H), while the third mutation associated
with late onset of HCM does not impede domain folding but may
interfere with interactions (R820G).
RESULTS
Sequence Alignments and Homology Models Predict
that D745G and P873H Would Likely Affect Domain
Folding While R820Q Would Likely Only Affect Domain
Interactions
A sequence alignment of eight homologs from chordates indi-
cates that D745 in C5, P873 in C7, and R820 in C6 are strictly
conserved (Figure 1). In addition, the equivalent of P873 is
conserved in the two other Fn-like cMyBP-C domains, C6 and
C9 (Figure 2), suggesting that this position may be critical in
maintaining the fold of the Fn domains in cMyBP-C. In contrast,
the positively charged R820 in C6 is not conserved in the equiv-
alent position in C7 and C9, where there is a substitution of a
negatively charged glutamate.
The solution structure of human C5 Ig-like domain has been
determined by NMR spectroscopy (PDB: 1GXE; Idowu et al.,
2003). Currently there are no structures available for the human
C6 or C7, although both are predicted to have Fn fold. For C6,
there are no available structures from any organism, but a BLAST
search (http://blast.ncbi.nlm.nih.gov/) (Altschul et al., 1990) iden-
tified the last module (residues 198–288) within the three-module
structure from human titin (PDB: 2NZI; Mrosek et al., 2007) as the106 Structure 24, 105–115, January 5, 2016 ª2016 Elsevier Ltd All rigclosest homolog with 36.3% identity. For C7, the homologous
mouse fast-twitch MyBP-C has been solved by NMR spectros-
copy and deposited in the PDB (PDB: 1X5Y), and has 60.4%
sequence identity to the human cMyBP-C. It is noteworthy that
the equivalent proline in PDB: 1X5Y to P873 is trans in all 20
deposited conformers, and this proline is strictly conserved in
all isoforms of MyBP-C, at least across mammals.
Homologymodels of the humanC6 andC7 cMyBP-C domains
were constructed using PDB: 2NZI and 1X5Y as templates,
respectively. The Swiss-Model homology modeling server
(http://swissmodel.expasy.org/; Biasini et al., 2014) was used
for automated structure prediction using the program ProMod-
II that implements energy minimization (Guex and Peitsch,
1997). The N and C termini of the C6 and C7 models were not
predicted to form any regular secondary structure. The model
quality was assessed using the QMEAN scoring function (Ben-
kert et al., 2011), and an overall QMEAN4 score of 2.72 (C6)
and 2.51 (C7) indicate that the models are of reasonable
quality.
The model structures for each of the domains (Figure 3) reveal
that all three mutation sites sit in loops within the vicinity of b
strands; those in C5 and C7 are largely buried while that in C6
is surface exposed. Indeed the side chain of the R820 in the hu-
man C6 model is fully exposed on the protein surface, and
replacement by the polar, uncharged glutamine would be un-
likely to affect the protein fold but could affect protein-protein
interactions.
In the NMR structure of human C5, D745 is mostly buried with
the side chain pointing toward a cavity within the C5 domain. Of
note, Y749 within this cavity is strictly conserved in the sequence
alignments of Figure 1, and, in themajority of the structures in the
deposited NMR ensemble, the hydroxyl group appears to form a
hydrogen bond to D745. Any loss in hydrogen bonding within the
cavity at this position, resulting from the D745G mutation, might
destabilize this region. It is also possible that the mutation to the
much smaller glycine may affect the folding of the domain.
The proline at position 873 is well conserved across myosin-
binding proteins, and the NMR structure for the mouse fast-
twitch C7 domain indicates that this proline side chain packs
well into the interior of the protein. As expected, this arrange-
ment is also reflected in the human C7 homology model, and it
is likely that the hydrophobic interactions mediated by the pro-
line side chain are important for the structural integrity of this
domain. The introduction of strain resulting from the P873H
mutation, with histidine being a much larger and hydrophilic res-
idue, is expected to be unfavorable and may destabilize the
protein fold.
In summary, it appears that the highly non-conservative
D745G and P873H mutations in C5 and C7 are likely to impact
interactions within the core domain structure and affect its
folding and/or stability, while the substitution of a positively
charged side chain with a polar, uncharged group in the
R820Q mutation of C6 would be unlikely to affect the domain
fold but could impact on interactions with binding partners.
Biophysical Characterization Supports Predictions from
Bioinformatics and Structural Models
Protein expression and solubility studies were undertaken to
obtain a set of constructs that would enable assessment of thehts reserved
Figure 1. Sequence Alignment of cMyBP-C Homologs from Divergent Chordates
Sequence alignment number at the top indicates relative position with respect to Genbank: NP_000247.2 (homo_sapiens, human cMyBP-C) domains: C5 (black;
R641–D770), C6 (blue; V771–P863) and C7 (green; F864–V964). Themutation sites are indicated by a red asterisk: D745 in C5 (position 106), R820 in C6 (position
181), and P873 in C7 (position 234). NCBI reference numbers are as follows: Genbank: NP_032679.2 (Musmusculus; mouse cMyBP-C), NP_001099960.1 (Rattus
norvegicus; rat cMyBP-C); NP_001070004.1 (Bos taurus; cow cMyBP-C), NP_001041571.1 (Canis lupus familiaris; dog cMyBP-C), NP_001037814.2 (Danio rerio;
zebrafish cMyBP-C), NP_990447.1 (Gallus gallus; chicken cMyBP-C), NP_001082167.1 (Xenopus laevis; frog cMyBP-C). The alignments are colored according to
the ClustalX color scheme with conservation threshold set to 15% for all sequences. See also Figure S1.structural impacts of each mutation. The set selected for study
included C5C6C7, C5C6*C7, C6*C7, C5*C6C7, C7, and C7*,
where mutated versions of each domain are indicated with an
asterisk (*). Constructs with cleavable histidine tags were used
whenever possible for ease of purification, with subsequent
cleavage to minimize complications in structural interpretation
from the presence of tags. However, C5*C6C7 showed exten-
sive degradation after cleavage, so characterization of the effect
of the D745G mutation was performed with a hexahistidine-
tagged construct denoted tC5*C6C7. An equivalent native
construct (tC5C6C7) with the same tag was also prepared for
direct comparison.
The presence of each mutation significantly affected the
solution behavior of each construct. During protein purification
by size-exclusion chromatography (SEC), the C5*C6C7 and C7*Structure 24, 10consistently eluted earlier from the column compared with the
corresponding wild-type constructs. For each construct,
multi-angle laser light scattering (MALLS) yielded the expected
molecular weight (MW) values for monomeric species (Figure S2
and Table S1) with tC5C6C7, C5C6C7, and C5C6*C7 each
migrating similarly, although C5C6*C7 consistently showed a
broad shoulder eluting before the main peak. This broad-shoul-
der peak corresponds to an MW of 104 kDa, but the
calculated values vary considerably across the elution peak,
steadily decreasing from a very high initial value consistent
with non-specific protein aggregation. C5*C6C7 elutes as a sin-
gle well-defined peak, but earlier than the other three-domain
constructs, indicating a molecule with a somewhat larger
Stokes radius and suggestive of a more extended overall
conformation.5–115, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 107
Figure 2. Sequence Alignment of Fibronectin-Like Domains of Human cMyBP-C
Sequence alignment number at the top indicates relative positions with respect to the human C7 domain (F864–V964). The P873 site in C7 is indicated by a red
asterisk (position 10 in the alignment), and R820 in C6 by a blue asterisk (position 52 in the alignment). The alignments are colored as in Figure 1. See also
Figure S1.SAXS and Fourier Transform Infrared Spectroscopy
Indicate that R820Q Has Minimal to No Impact on C6
Fold
SAXS data, acquired and analyzed as summarized in Table 3 in
the Experimental Procedures, show that the three-domain struc-
ture of C5C6C7 is preserved in the C5C6*C7 construct. Compar-
ison of the P(r) profiles and Rg values for C7, C6*C7, and
C5C6*C7 (Figure 4A) neatly show the presence of a one-, two-,108 Structure 24, 105–115, January 5, 2016 ª2016 Elsevier Ltd All rigand three-domain structure, respectively, accompanied by the
expected increase in the radius of gyration (Rg; from 15.7 to
25.6 to 39.4 A˚) and maximum dimension (dmax; from 60 to 90
to 145 A˚) for C7, C6*C7, and C5C6*C7, respectively (for P(r)-
derived values, see Table 1). Furthermore, the positions of the
maxima in the P(r) functions from each construct overlap, indi-
cating that the corresponding individual domains are of similar
dimensions, with each additional domain giving rise to aFigure 3. Location of Mutation Sites D745,
R820, and P873 in Domain Model Structures
Highlighting Predicted Interactions with
Surrounding Residues
Overall domain structure and close-up view of the
mutation site is shown at left and middle,
respectively, with a cross-section view of the
protein surface near the mutation site and pre-
dicted interactions with surrounding residues
shown on the right. Surface (cyan) and secondary
structure elements (blue) are shown with mutation
sites highlighted in purple. Side chains of residues
within 4 A˚ of the mutation sites are represented as
sticks.
(A) The lowest energy state from the NMR
ensemble for human C5 (PDB: 1GXE) showing
the D745 side chain pointing toward a small
cavity to form a hydrogen bond within the protein
interior. K685–K715 (red) indicates a flexible
loop that forms an arch over the cavity that D745
packs into.
(B) The homology model of human C6 showing the
surface-exposed R820 side chain.
(C) The homology model for human C7 showing
the P873 backbone pointing into a hydrophobic
pocket.
hts reserved
Figure 4. SAXS Modeling Results Showing
the Characteristic Three-Domain Structure
for C5C6C7 and C5C6*C7
(A) P(r) profiles for C5C6C7 (black) and C5C6C*C7
(red), C6*C7 (blue), and C7 (green). Profiles for
C5C6C7 and C5C6*C7 are scaled for equal
areas, while C6*C7 and C7 are scaled to have
approximately equal peak height to facilitate
comparison with C5C6C7. C5C6*C7, C6*C7, and
C7 data are from experiment 1, and C5C6C7
data are from experiment 2. Error bars repre-
senting propagated statistical errors for I(q) and
P(r) are included but are mostly smaller than the
symbols.
(B) Comparison of C5C6*C7 (red), C6*C7 (blue),
and C7 (green) dummy residue models, each
calculated using experiment 1 data.
(C) Rigid-body model (from D) I(q) fits to the
C5C6C7 (experiment 1) and C6*C7 (experiment 2)
I(q) data. The fits by eye are reasonable, with
higher than ideal c values (2.6 and 3.6, respec-
tively) as expected given the inherent limitations of
the NMR and homology models for the domains
and the lack of information on the domain linkers.
Error bars representing propagated statistical er-
rors for I(q) and P(r) are included but are mostly
smaller than the symbols.
(D) Comparison of averaged and filtered dummy
residue sphere models for C5C6C7 (gray) and
C5C6*C7 (red) with the rigid-body optimized
model (cyan ribbon) based on the domain structures in Figure 3; each calculated using the extrapolated data from experiment 2. Also shown is the dummy residue
reconstruction for C6*C7 (experiment 1 data) in the same orientation as in (B) with the rigid-body optimized model overlaid.
See also Figures S2 and S3; Table S1.shoulder in the P(r) function corresponding to the most frequent
vector lengths between neighboring domains (at 50 A˚) in the
two- and three-domain constructs and between next nearest-
neighbor domains (at 90 A˚) in the three-domain construct.
Finally, comparison of the SAXS-derived structural parameters
(Table 1) and P(r) profiles for C5C6C7 and C5C6*C7 (Figure 4A)
show no significant differences in the derived structural param-
eters and the P(r) profiles.
Structural modeling of the scattering data supports the inter-
pretation of the P(r) and Guinier analyses. Dummy atom recon-
structions (Figure 4B) from the C7, C6*C7, and C5C6*C7 data
give one-, two-, and three-domain shapes that can be overlaid
to show that the domains maintain similar relative shapes and
dispositions. Rigid-body modeling against data for C6*C7 and
C5C6C7 using the model structures for the domains in Figure 3
shows relatively good agreement with the scattering profiles
(Figure 4C), and the resultant atomistic model structures overlay
with the respective dummy residue models (Figure 4D). For
completeness, the C5C6C7 and C5C6*C7 dummy residue re-
constructions are also shown to have the same overall shape
(Figure 4D, red and gray overlaid models). Figure S3 shows
log-log and Guinier plots of the SAXS data, which, along with
the scattering derived parameters in Table 1, demonstrate the
data quality and the fact that the samples are monodisperse so-
lutions of proteins of the expected MW.
Complementing the scattering results, Fourier transform
infrared (FTIR) spectra for C5C6C7, C5C6*C7 provide support
for the homology models for the domains and the conclusion
that the R820Qmutation has no significant impact on secondaryStructure 24, 10structure content, particularly with respect to the b-strand con-
tent (Figure 5 and Table 2). For calibration of the FTIR results, a
survey of 21 water-soluble proteins found that percentage sec-
ondary structure assignments based on FTIR and the Amide I0
band assignments were within 3% of the values predicted
from the X-ray crystal structures (Byler and Susi, 1986). The es-
timate of b-strand structure for the combinedNMR structure plus
homology models for C5C6C7 agrees well with the estimated
b-strand content from FTIR. There is some greater variability (a
few percent) for turns and coils, as might be expected for a com-
bined NMR/homologymodel. Comparison of results for C5C6C7
and C5C6*C7 show that the estimates for b-strand content are
within 1%, while estimates for the coils, turns, and aggregated
b strands differ by less than 3%. These latter differences are of
the same order as the differences in estimated aggregated
b-strand content. Overall these results strongly support the
conclusion that the R820Q mutation has no significant impact
on the secondary structure or fold of C6.
SAXS and FTIR Data Indicate that D745G Results in a
Loss of a Folded Domain in the Three-Domain C5C6C7
Construct
As noted above, the impact of the D745Gmutation could only be
assessed using tagged constructs, due to the extreme sensitivity
of constructs containing this mutation to degradation upon at-
tempts to remove the tags. By itself, this observation suggests
that the fold of C5 is significantly compromised by the mutation.
The FTIR data (Figure 5 and Table 2) confirm there is a significant
loss of b structure and a substantial increase in the band5–115, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 109
Table 1. SAXS-Derived Structural Parameters
C5C6C7 C5C6*C7 tC5C6C7 tC5*C6C7 C6*C7 C7
Guinier Results
Experiment 1 Rg (A˚) 37(1) 25(2) 15.3(1)
qRg range (A˚
1) 0.65–1.3 0.72–1.22 0.57–1.3
Experiment 2 Rg (A˚) 37 (2) 38 (2) 40 (2) 44 (2)
qRg range (A˚
1) 0.54–1.3 0.54–1.3 0.56–1.16 0.56–1.16
P(r) Results
Experiment 1 Rg (A˚) 39.38 (9) 25.58 (4) 15.53 (3)
dmax 145 90 60
q range (A˚1) 0.017–1.189 0.028–0.305 0.039–0.251
Experiment 2 Rg (A˚) 39.38 (7) 40.3 (1) 42.6 (5) 45.6 (9)
dmax 141 150 169 200
q range (A˚1) 0.014–0.193 0.015–0.193 0.018–0.193 0.02–0.193
Protein mg ml1 Range for Extrapolation to Infinite Dilution
Experiment 1 0.9–3.1 0.6–5.1 5.7–11.7
Experiment 2 0.7–3.4 0.5–1.9 0.3–1.4 0.2–1.2
MW from I(0) Valuesa
Experiment 1 37,427 23,249 11,803
Experiment 2 38,204 35,416 39,708 37,055
Ratio of I(0) Derived to Expected MW 1.07 0.99 1.06 0.99 1.10 1.10
aMW values are those calculated from I(0) for the lowest concentration measured for each extrapolated concentration series.associated with aggregated b strands at the high concentrations
required for FTIR measurement. It was nevertheless possible to
prepare samples for SAXS measurement at lower concentra-
tions that were monodisperse, as assessed by MW calculations
(Table 1). Comparison of the P(r) profiles for tC5C6C7 and
tC5*C6C7 (Figure 6A) shows a loss of intensity in the second
shoulder at 80 A˚ that is predicted from the loss of a structured
third domain while the Rg and dmax values are substantially
increased, by 6 A˚ and 30 A˚, respectively (Table 1). Dummy
residue reconstructions support the interpretation of the P(r)
analysis in that the tC5C6*C7 structure is more extended than
tC5C6C7 and also has a distinctive shape (red and cyan repre-
sentations, Figure 6B).
NMR and FTIR Data Indicate a Loss of Secondary
Structure Resulting from the P873H Mutation
While the triple-domain constructswere too large for reliable struc-
tural comparison using 1D 1H NMR spectroscopy, the much
smaller C7 domain gave well-dispersed and sharp peaks from
backbone amide protons in the 1D 1H NMR spectrum (e.g. be-
tween5and6.5and8.5–10ppm) (Figure7), indicatingawell-folded
domain. In contrast, no well-dispersed, sharp peaks are observed
forC7*,with thevastmajorityof peaksclustered in themiddleof the
spectrumcharacteristic of anunfoldedprotein. The sharppeak just
beyond10ppmisexpected toarise fromthe tryptophansidechain.
The FTIR data (Table 2) for C7 and C7* are consistent with the
NMR results, indicating that C7 is folded. Furthermore, the
derived secondary structure content for C7 is in excellent agree-
ment with that predicted from the homology model. In contrast,
the FTIR spectrum for C7* shows a substantial decrease in b
strand and an increase in the band associated with aggregated
b strand. While it was possible to obtain monodisperse C7 for110 Structure 24, 105–115, January 5, 2016 ª2016 Elsevier Ltd All rigSAXS analysis, the limited solubility of C7* prohibited ameaning-
ful comparative SAXS experiment.
DISCUSSION
Our combined bioinformatics analysis, homology modeling, and
biophysical characterization of the C5, C6, and C7 modules of
cMyBP-C provides convincing evidence that the R820Q muta-
tion in C6 does not affect the overall protein fold, whereas
D745G and P873H in C5 and C7, respectively, do interfere with
domain folding. These differential structural impacts appear to
be correlated with differential outcomes for HCM patients.
The P873H mutation in C7 has been reported as a homozy-
gous HCMmutation (Nanni et al., 2003) with moderate to severe
hypertrophy, and P873L also has been reported in a patient pre-
senting with decompensated congestive heart failure (Probst
et al., 2011). Considered in combination with the observed strict
conservation of P873, it appears that the specific interactions of
P873 within C7 may be critical for maintaining a correct fold. The
C7 domain is required for proper incorporation of cMyBP-C into
the thick filament (Zhang et al., 2014), and thus is not surprising
that the P873Hmutation that results in amisfolded domainmight
well affect sarcomere development. P873 also has been identi-
fied as a compound heterozygous mutation with D745G in C5,
associated with severe left ventricle hypertrophy diagnosed at
a relatively young age (29 years) (Ingles et al., 2005). Further-
more, in a study of single and multiple mutations in a cohort of
HCM patients, about 5% of the patients carried more than one
mutation and these patients appeared to develop more severe
clinical phenotype; specifically, the patients had a significantly
greater left ventricular wall thickness than single-mutation pa-
tients (Ingles et al., 2005).hts reserved
Figure 5. FTIR Spectra with Deconvolution
Results for Native and Mutated Forms of
C5C6C7 and C7
The Amide I0 region of each measured spectrum
(1,600–1,690 cm1) is shown in red with the cor-
responding deconvolution in blue, except the
band attributed to aggregated b strands, shown as
a dashed line. Amide band frequency assignments
are given in Table 2.The majority of clinically linked cMyBP-C mutations are trun-
cations, frame shifts, or splice variants, although missense vari-
ants still account for more than 40% (reviewed in Harris et al.,
2011; Lee et al., 2015; Carrier et al., 2015). It has been suggested
that cMyBP-Cmutations mainly cause HCM through haploinsuf-
ficiency. This suggestion is supported by the inability to detect
truncated or mutated cMyBP-C proteins in HCM patients
despite the presence of mutant mRNA transcripts, concomitant
with a reduction of the observed cMyBP-C expression level
(Marston et al., 2012; van Dijk et al., 2009). Our results demon-
strate that the D745G and P873Hmutations cause major disrup-
tion to the structural integrity of the C5 and C7 domains
and result in much lower yields of protein when expressed in
Escherichia coli, increased protein aggregation, and protein mis-
folding. Assuming the effects of these mutations can be trans-
lated to full-length cMyBP-C in vivo, one might expect the major
quality control systems in the myocytes (e.g. the ubiquitin-pro-Structure 24, 105–115, January 5, 2016teasome system and autophagy-lyso-
some pathway) to remove the mutant
proteins. Misfolding of both C5 and C7
could have an additive impact, perhaps
increasing the likelihood that the cell ma-
chinery would target the misfolded pro-
tein for elimination, and resulting in the
observed increased severity in clinical
outcomes.
While haploinsufficiency seems a likely
outcome for many HCM-linked muta-
tions, the additional possibility of
missense mutants being incorporated
into the sarcomere, possibly alongside
wild-type cMyBP-C, cannot be dis-
counted. Indeed the fact that different
phenotypes arise from different muta-
tions argues against simple haploinsuffi-
ciency as the explanation for all of the
observed effects. Furthermore, in a
recent study of the HCM-causing muta-
tion E258K, De Lange et al. (2013) engi-
neered murine cardiac tissue lacking
endogenous mouse cMyBP-C and suc-
cessfully used it to express human wild-
type and E258K cMyBP-C. The E258 res-
idue is at the boundary of C1 and the
motif, downstream of the phosphoryla-
tion sites of the motif (S275, S284,
S304) in the region that, in vitro at least,
is disordered. De Lange et al. (2013)found that the E258K mutation was successfully incorporated
into the cardiac sarcomere but that the cMyBP-C interaction
with S2 was disrupted, which significantly affected the contrac-
tile kinetics but not cardiac cell survival.
The continual process of contraction and relaxation in cardiac
muscle involves dynamic changes in sarcomere lengths and
alterations to the distances between the thick and thin filaments.
Our picture of cMyBP-C function has it interacting dynamically
with actin and myosin S2, fine-tuning regulatory control in
contraction while also providing a link between the thin and thick
filaments. We previously suggested that it may play a role in con-
trolling the dynamic inter-filament spacing that is critical to
healthy heart function and development (Whitten et al., 2008b).
Intriguingly, both N- and C-terminal domains of cMyBP-C have
been shown to influence actin rotational dynamics during the
contractile cycle in a phosphorylation-dependent manner (Col-
son et al., 2012). In this context, the central domains would beª2016 Elsevier Ltd All rights reserved 111
Table 2. FTIR Secondary Structure Analysis
Predicteda
C5C6C7 C5C6C7 C5C6*C7 tC5C6C7 tC5*C6C7 Predicteda C7 C7 C7*
Helix 1 0 0 0 0 1 0 0
b strands 45 45 44 45 36 50 52 35
Turns 25 21 25 24 24 25 24 27
Coils 18 24 23 24 18 22 22 25
Aggregated b strands – 10 8 6 22 – 2 13
aPredicted secondary structure percentages assigned for each construct are based on the models for each domain in Figure 3 and do not include the
His-tags. Amide I band frequencies assignments used in interpretation of deconvolution results were (cm1): helix (1,652); b strands (1,671, 1,635);
turns (1,695, 1,686, 1,660); coils (1,645); aggregated b strands (1,615).subjected to significant movements and potential stresses dur-
ing the contractile cycle. The integrity of their structural fold, as
well as their disposition with respect to each other, would be
critical with regard to their role in controlling the dynamics of
the inter-filament spacing and actin rotational dynamics. If a
variant of cMyBP-C that has a misfolded or less stable domain
were incorporated into the sarcomere, it could thus affect the
sarcomere dynamics and affect heart development. Further
evidence for the central domains of cMyBP-C having a role in
controlling filament dynamics has been observed in studies of
the effects of post-translational S-glutathionylation at sites in
C4 and C5 (Patel et al., 2013).
Missense mutations in cMyBP-C are commonly, though not
always, associated with a more benign form of HCM character-
ized by late-onset hypertrophy and a lower incidence of sudden
cardiac death (reviewed in Harris et al., 2011; Lee et al., 2015;
Carrier et al., 2015). This progression is suggestive of a cumula-
tive effect resulting from an initially tolerable but ultimately dis-
ease-conferring effect on the sarcomere structure and dynamics
resulting from the mutation. The R820Q mutation is associated
with delayed onset of HCM that progresses in the elderly to
dilated cardiomyopathy, which is characterized by wall thinning
and impaired systolic function (Konno et al., 2003). This mutation
does not disrupt the protein fold, but does show evidence for the
potential to affect protein-protein interactions in the MALLS
data. Specifically, preparations of the C5C6*C7 construct
show a significant component of (non-specifically) aggregated
protein that is not observed for C5C6C7. The C6 domain is one
of the five cMyBP-C domains that have not been solved by
NMR or crystallography for any cardiac isoform, and there is little
information on potential interactions. Yeast two-hybrid and sur-
face plasmon resonance studies (Moolman-Smook et al., 2002)112 Structure 24, 105–115, January 5, 2016 ª2016 Elsevier Ltd All rigindicated an interaction between C5 and C8 that shows reduced
affinity for two HCM-linked mutations in C5, and also an interac-
tion between C7 and C10. Based on these data, Moolman-
Smook et al. (2002) proposed the ‘‘collar model’’ in which
C5C6C7 interacts with C8C9C10 in a staggered parallel arrange-
ment that circles the thick filament. They further suggest that
the interaction could dynamically form and release to affect
cross-bridge formation. In this model, R820 could be positioned
at an interface with C9 and affect such an interaction. In the
alternative ‘‘linear’’ model the C-terminal domains C8 through
C10 are arranged linearly along the thick filament backbone,
consistent with their being the principal interaction sites for
myosin heavy chain and titin (Squire et al., 2003), and no interac-
tion with C6 is inferred. The combination of the distinct pheno-
type and the lack of any evidence for structural disruption of
the C6 domain for the R820Q mutation is highly suggestive
that this domain does have some key interaction within the
sarcomere and is required for sustaining normal sarcomere
development.EXPERIMENTAL PROCEDURES
Sequence Analysis, HomologyModeling, Protein Structure Analysis,
Visualization, and Representation
Protein sequence for the central domains of human cMyBP-C (R641–V964)
was used in a protein BLAST search of non-redundant protein sequences
(http://blast.ncbi.nlm.nih.gov/; Altschul et al., 1990) to identify homologs
from divergent species. The BLAST search parameters were set to exclude
non-human primates, model entries, and predicted sequences (XM/XP). Se-
quences were extracted from the RefSeq database (Pruitt et al., 2014) avail-
able from the NCBI. Whenmultiple isoformswere identified fromeachorganism,
the closest homolog was chosen for sequence analysis. Sequence alignment
was performed on the Clustal Omega (Sievers et al., 2011) web server (availableFigure 6. P(r) Profiles and Dummy Residue
Models for tC5C6C7 and tC5*C6C7
(A) The P(r) profiles for tC5C6C7 (cyan) and
tC5*C6C7 (wine). Error bars representing propa-
gated statistical errors for I(q) are included but are
mostly smaller than the symbols.
(B) The dummy residue models corresponding
to the data in (A) are color coded the same as the
P(r)s. The tC5C6C7 model (cyan) is superimposed
on that for C5C6C7 (gray) (from Figure 4B), and
from this overlay the extra volume expected due to
the presence of the His-tag is evident.
See also Figures S2 and S3; Table S1.
hts reserved
Figure 7. Amide region from 1D 1HNMRSpectra of C7 (blue) and C7*
(orange)at http://www.ebi.ac.uk/Tools/msa/clustalo/http://www.ebi.ac.uk/Tools/msa/
clustalo/), and the resulting alignment files were visualized and processed in Jal-
View (Waterhouse et al., 2009).
The Swiss-Model homology modeling server was used for structure predic-
tion of the following domains using as templates various crystal or NMR struc-
tures: C5* (PDB: 1GXE; 99% identity), C6 and C6* (PDB: 2NZI; 36% identity),
C7 and C7* (PDB: 1X5Y; 60% identity) PDB: 1X5Y. Figure S1 shows ClustalX
alignments of human andmouse C6 and C7 domains with the sequences used
for homology modeling, showing conservation across species and isoforms.
PyMOL (Molecular Graphics System, version 1.7.0.5) was used for protein
structure visualization and presentation.
Secondary structure assignment for comparison with FTIR analyses used
the STRIDE web server (http://webclu.bio.wzw.tum.de/stride/; Heinig and
Frishman, 2004), which categorized the structural content into the four groups
helix, strand, turn, and coil, where coil is defined as any assignment that
cannot be categorized into the other three groups, and therefore includes
disordered and random unstructured regions.
Cloning
Unless otherwise stated, all domains, protein constructs, and gene fragments
refer to the gene coding for human cMyBP-C (GenBank: NG_007667). Frag-
ments were subcloned from a codon optimized synthetic gene encoding the
full-length human cMyBP-C for E. coli expression that included the R820Qmu-
tation (Jeffries et al., 2011). Sequence-specific primers containing 50 BamHI
and 30 EcoRI restriction endonuclease sites were designed, and PCR was
performed to isolate gene fragments encoding for the C7 (864–964), C6*C7
(641–964) and C5C6*C7 (641–964) domains. The isolated PCR products
were subsequently directionally subcloned using the BamHI and EcoRI restric-
tion sites into a modified pET28a expression vector encoding a cleavable
hexahistidine tag on the N terminus (HMHHHHHHGTLEVLFQGPGS). The
wild-type construct and C7* mutant were subsequently synthesized from the
corresponding expression vectors by site-directedmutagenesis. The resulting
gene fragments were verified to have the correct DNA sequence by Sanger
sequencing (Australian Genome Research Facility) using vector- and insert-
specific primers.
Protein Expression and Purification
Purified expression vectors for C5C6C7, C5C6*C7, tC5C6C7, tC5*C6C7,
C6*C7, C7, and C7* were individually transformed into E. coli Rosetta2(DE3)
pLysS cells (Invitrogen). Protein expression was carried out in Luria broth
supplemented with 33 mg/ml chloramphenicol and 60 mg/ml ampicillin.
Initially each culture was grown at 37C to an optical density at 600 nm of
0.6. The resulting cultures were then induced with 1 mM isopropyl b-D-1-thio-
galactopyranoside, and protein expression was carried out at 15C for 18 hr.
Cells were harvested via centrifugation at 5.000 3 g (10 min, 4C), and the
pelleted cells were immediately flash-cooled in liquid nitrogen and stored
at 80C.
Re-suspension and lysis of frozen cell pellets was carried out using Bacterial
Protein Extraction Reagent (Pierce) supplemented with 20 mM imidazole,
1 ml/ml b-mercaptoethanol, 100 mg/ml each of DNase, RNase, and lysozyme,
and appropriate quantities of cOmplete protease inhibitor cocktail tablet
(EDTA-free; Roche). All subsequent steps were carried out at 4C. Cell debris
was removed by ultracentrifugation at 169,000 3 g (rotor 60Ti; BeckmanStructure 24, 10Coulter) for 60 min. The clarified supernatant was applied to pre-packed nickel
affinity column (5 ml/50 ml supernatant; GE Healthcare) pre-equilibrated with
buffer A (250 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine, 25 mM Tris-
HCl [pH 7. 5]) supplemented with 20 mM imidazole. Protein chromatography
was monitored and controlled using an AKTA purifier (GE Healthcare).
Following sample loading, the protein-bound columns were extensively
washed with buffer A until A280 values reached baseline. Non-specifically
bound contaminants were removed by washing the columnswith buffer A sup-
plemented with 30 mM imidazole. Finally the bound cMyBP-C proteins were
eluted with buffer A supplemented with 250 mM imidazole.
All samples were dialyzed overnight against buffer A in the presence of
PreScission protease to simultaneously remove the N-terminal hexahistidine
tag and to reduce imidazole concentration in the sample. Dialyzed cMyBP-C
fragments for which the histidine tag was successfully cleavedwere re-applied
to pre-packed nickel affinity columns to obtain the untagged proteins. All pro-
teins were further purified by SEC (Superdex75; GE Healthcare) using buffer A
supplemented with 1 mM EDTA and 0.02% sodium azide. The purity of the
samples was judged to be >95% using SDS-PAGE.
SEC-MALLS
SEC-MALLS experiments were performed using a Superdex75 column (GE
Healthcare) attached to an AKTA purifier (GE Healthcare) with an in-line
miniDAWN light-scattering unit and an Optilab DSP refractometer (both from
Wyatt Technology) forMWdetermination. Samples of 100–500 mgwere loaded
on a 100-ml loop and eluted isocratically using buffer A at 0. 5 ml/min. The sys-
tem was calibrated to an absolute scale using intrinsic Rayleigh scattering in
toluene to determine the relative molecular masses. A uniform refractive index
to a concentration gradient (dn/dc) of 0.19 ml/g was assumed for all proteins.
MALLS and refractive index data were collected and analyzed using ASTRA
software (Wyatt Technology).
SAXS
SAXS data were measured at the Australian Synchrotron on the SAXS/WAXS
beamline (Kirby et al., 2013) at two separate visits using independent sample
preparations (experiments 1 and 2) with the data collection parameters pre-
sented in Table 3. Data were reduced to I(q) versus q (IðqÞ= 4p sin q=l, where
2q is the angle between the incident and scattered X-rays, and l their
wavelength, using the software scatterBrain (http://www.synchrotron.org.au/
aussyncbeamlines/saxswaxs/software-saxswaxs). Intensities were placed
on an absolute scale using the known scattering from H2O. All samples were
prepared by dialyzing against buffer A with 0. 02% NaN3 at 25
C, and a sol-
vent-scattering blank taken from the endpoint dialysate was measured before
each sample. Protein scattering was obtained by subtraction from the sample
scattering the corresponding solvent blank scattering. MW estimates for the
proteins were made using the method of Orthaber et al. (2000). Values for
contrast and partial specific volumes were determined using the program
MULCh (Whitten et al., 2008a). SAXS data analysis and modeling used the
ATSAS program package (Petoukhov et al., 2012), with the specific programs
used specified in Table 3 along with the data ranges used in each calculation.
DAMMIF calculations were submitted to ATSAS online, with P1 symmetry
for 20 independent runs that yielded a set of similar shapes for each construct
with normalized spatial discrepancy values <1 as follows (SDs in parentheses):
experiment 1: C5C6*C7 0.704 (0.024), C6*C7 0.669 (0.031), C7 0.597 (0.020);
experiment 2: C5C6C7 0.736 (0.036), C5C6*C7 0.794 (0.033), tC5C6C7 0.667
(0.034), tC5C6*C7 0.0695 (0.063). Rigid body modeling of the two- and three-
domain constructs used SASREF and the NMR model for C5 and the homol-
ogy models in Figure 3 with the relevant C and N termini constrained to be less
than 10 A˚ apart, with each domain free to re-orient to optimize the fit with the
SAXS data.
FTIR Spectroscopy
FTIR spectra were obtained using the BioATR II accessory (Bruker Optics)
installed on a Bruker Tensor 27 spectrometer equipped with a liquid nitro-
gen-cooled MCT detector. The BioATR II cell was continuously purged with
dry nitrogen to minimize water vapor in the IR-beam path, and the temperature
of the sample cell was maintained at 25C by a refrigerated circulator water
bath (Ministat 125; Huber). All experiments were performed at 25C with
samples used for NMR measurements, dialyzed against buffer A. The sample5–115, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 113
Table 3. SAXS Data Acquisition, Sample Details, and Software Employed
Instrumentation Australian Synchrotron SAXS beamline
Experiment 1: 30 June 2014 Experiment 2: 18 April 2015
Data Collection Parameters
Beam geometry (mm) 250 3 150 250 3 150
q range measured (A˚1) 0.01–0.476 0.006–0.344
Exposure time (s) 1 s 3 24 frames 1 s 3 44 frames
Temperature (C) 22 22
Sample Details C5C6*C7 C6*C7 C7 C5C6C7 C5C6*C7 tC5C6C7 tC5C6*C7
Partial specific volume (n, cm3 g1) 0.735 0.736 0.735 0.735 0.735 0.735 0.735
Contrast from sequence and solvent
constituents (Dr, 1010 cm2)
2.841 2.826 2.794 2.841 2.841 2.839 2.820
MW from sequence (Da) 35,709 21,498 10,734 35,738 35,709 37,576 37,519
Software Employed for Data Reduction, Analysis, and Interpretation
SAXS data reduction ScatterBrain
Calculation of expected MW, Dr, and n values MULCh
SAXS data analysis: extrapolation to infinite dilution, Guinier, and P(r) ATSAS 2.6.0 SAS Data Analysis
Ab initio dummy residue modeling DAMMIF (via ATSAS online)
Atomic structure modeling SASREF (via ATSAS online)
3D graphic model representations PyMOLcell was washed five times with buffer A between sample measurements
and the cleanliness of the attenuated total reflectance crystal was monitored
by the measurement of a baseline of the buffer-covered crystal before and
after washing. A reference absorbance spectrum of buffer was measured
before each sample measurement. Reference and sample measurements
collected 128 scans within the 1,300–1,800 cm1 region and using a resolution
of 4 cm1.
Each raw sample spectrum was processed to compensate for atmospheric
water vapor and carbon dioxide. The resulting spectra were imported into the
GRAMS AI software package (Thermo Scientific) for baseline correction and
further analysis. The amide I peak (1,600–1,690 cm1) (Adochitei and Dro-
chioiu, 2011; Byler and Susi, 1986; Kong and Yu, 2007), which arises primarily
from the peptide backbone carbonyl stretching vibrations, consists of overlap-
ping component bands corresponding to the different secondary structure
components: a helices, b sheets, turns, and random structures. Second-deriv-
ative analysis and Fourier deconvolution was used to aid in identifying and
fitting the component bands and determining their relative intensities. Peak
fittingwas performed interactively in GRAMSAI startingwith the smallest num-
ber of peaks and increasing the number as more regions were identified in the
residual plot. For all sample spectra, multiple mathematical models were
generated that satisfied peak positions in the context of the protein secondary
structured components. The (software-derived) converged solution or local
minimum with the best correlation R2 value was chosen as the final solution.
The secondary structure content for each sample was represented as the rela-
tive percentage area under each corresponding peak.
NMR Spectroscopy
NMR spectra were recorded using a Bruker AVIII 800-MHz NMR spectrometer
equipped with a triple-resonance TCI cryogenic probe. The concentrations of
C7 and C7* were adjusted to 250 mM. All experiments were recorded at 298 K
in buffer A adjusted to pH 7.0 and supplemented with 0.02% NaN3 and 10%
D2O (v/v). Sodium 2,2-dimethyl-2-silapentane-5-sulfonate was used as the in-
ternal chemical shift reference. Spectra were processed with Topsin 2.1
(Bruker).
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